MedTrace Logo

Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma

NCT01617213 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2013-06-21

No results posted yet for this study

Summary

This trial will determine the feasibility and efficacy of lenalidomide as maintenance therapy in Multiple Myeloma patients treated with dose intensive chemotherapy (Melphalan 200 mg/m2) with autologous PBSC transplant.

Conditions

Interventions

DRUG

Melphalan

200 mg/m2/IV

DRUG

Lenalidomide

10 mg daily continuously for the first 3 months, then increased to 15 mg daily as long as the patient tolerates the drug.

Sponsors & Collaborators

  • University of Virginia

    lead OTHER

Principal Investigators

  • Mary J. Laughlin, MD · University of Virginia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2015-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01617213 on ClinicalTrials.gov